醒脑静联合尼莫地平对高血压脑出血患者NIHSS及ADL评分影响.docVIP

醒脑静联合尼莫地平对高血压脑出血患者NIHSS及ADL评分影响 　　【摘要】 目的 研究醒脑静联合尼莫地平对高血压脑出血（HCH）患者美国国立卫生研究院卒中量表（NIHSS）及日常生活能力量表（ADL）评分的影响。方法 68例HCH患者， 随机分为对照组和观察组， 各34例。对照组患者给予醒脑静进行常规治疗， 观察组患者给予醒脑静联合尼莫地平治疗， 均治疗4周。比较两组患者治疗前后的NIHSS评分以及出院3个月后的日常生活能力。结果 治疗4周后， 观察组患者NIHSS评分（6.92±6.84）分低于治疗前的（17.51±3.26）分， 对照组患者NIHSS评分（11.42±7.31）分低于治疗前的（17.60±2.73）分， 且观察组的NIHSS评分低于对照组， 差异有统计学意义（P0.05）。出院3个月后， 观察组患者日常生活能力治疗有效率97.06%明显高于对照组的70.59%， 差异有统计学意义（P0.05）。结论 醒脑静联合尼莫地平治疗HCH患者具有较好的治疗效果， 还可改善患者的神经缺损功能， 值得推广。 　　【关键词】 高血压脑出血；醒脑静；尼莫地平；美国国立卫生研究院卒中量表；日常生活能力量表 　　DOI：10.14163/j.cnki.11-5547/r.2018.13.059 　　【Abstract】 Objective To study the effect of Xingnaojing combined with nimodipine on National Institutes of Health Stroke scale （NIHSS） and activity of daily living scale （ADL） scores in patients with hypertensive cerebral hemorrhage （HCH）. Methods A total of 68 HCH patients were randomly divided into control group and observation group， with 34 cases in each group. The control group received Xingnaojing for conventional therapy， and the observation group received Xingnaojing combined with nimodipine for treatment. After 4 weeks of treatment， comparison were made on NIHSS score before and after treatment and daily living 　　3 months after discharge between the two groups. Results After 4 weeks of treatment， the observation group had lower NIHSS score as （6.92±6.84） points than （17.51±3.26） points before treatment， and the control group had lower NIHSS score as （11.42±7.31） points than （17.60±2.73） points than before treatment. The observation group had lower NIHSS score than the control group， and their difference was statistically significant （P0.05）. 3 months after discharge， the observation group had obviously higher treatment effective rate of activity of daily living as 97.06% than 70.59% in the control group， and the difference was statistically significant （P0.05）. Conclusion Combination of Xingnaojing and nimodipine shows good treatment effect in treating HCH patients， and it can improve the neurological de